AstraZeneca PLC
AZNStock
$169.29+21.86%52W
Market Cap$191.75B
P/E25.13x
Div yield1.95%
Beta1.39
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-21.07%
Price vs S&P 500 (4W)-5.07%
VGM Score51.84
Market Capitalization$191.75B
P/E Ratio (Annual)25.13x
Indicated Dividend Yield (Annual)1.95%
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.08
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
AZNAstraZeneca PLC | C | B | C | $169.29 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
| BMYBristol-Myers Squibb Co. | B | C | B | $60.51 |
About
AstraZeneca is a multinational pharmaceutical company formed in 1999 through the merger of Sweden's Astra and UK-based Zeneca. The company develops and markets branded drugs across oncology (over 40% of revenue), cardiovascular and metabolic diseases (20%+), rare diseases, and respiratory and immunology. Its revenue is geographically diversified, with approximately one-third of sales derived from the United States and the remainder from international markets.